Study Shows Semaglutide Reduces Cardiovascular Events in People With Overweight or Obesity but Not Diabetes
The Brigham was part of a trial that shows for the first time that the weight loss drug semaglutide lowers the incidence of death from cardiovascular causes in those with overweight or obesity but not diabetes. Jorge Plutzky, MD, discusses the findings and implications for clinical care.
Read More...